ArticleJournal of pain research2025
Oxymatrine Alleviates Central Post-Stroke Pain in Rats by Reducing the Inflammatory Response.
Article in Journal of pain research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Purpose: Central post-stroke pain (CPSP) is directly caused by cerebrovascular diseases that affect the central somatosensory system. It is a serious, chronic central neuropathic pain that responds poorly to first-line drugs. Oxymatrine (OMT), a monomer derived from the traditional Chinese medicine Methods: Gene Ontology (GO) enrichment analysis was initially employed to elucidate the role of OMT on CPSP target proteins in terms of gene function. Then the CPSP model was induced through focal hemorrhage in the ventral posterolateral nucleus (VPL). Rats were randomly assigned to five groups (n = 10): sham + NaCl, CPSP + NaCl, and CPSP + OMT (100 mg/kg, 200 mg/kg, 400 mg/kg). Daily intraperitoneal injections of NaCl or varying doses of OMT were administered from days 7 to 14 after model establishment, and paw withdrawal mechanical thresholds (PWMT) were assessed. The optimal OMT dose (200 mg/kg) was determined based on PWMT measurements. On day 14, inflammatory markers (IL-1β, IL-6, TNF-α) and alterations in microglia and astrocyte activity at the thalamic lesion site were analyzed. Results: Elevated levels of IL-1β, IL-6, and TNF-α ( Conclusion: OMT mitigates central post-stroke pain in rats by attenuating the inflammatory response at the thalamic lesion site.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.